Cargando…

Clinical predictors of symptom improvement failure in gastroparesis

BACKGROUND: The aim of this study was to determine clinical predictors of gastroparesis outcomes. METHODS: Between September 30, 2009 and January 31, 2020, we identified patients with gastroparesis diagnosed based on a (99m)Tc sulfur-labeled gastric emptying test. The patients who had no symptom imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Amjad, Waseem, Doycheva, Iliana, Kamal, Faisal, Malik, Adnan, Pandu, Asha, Shabbir, Muhammad Asim, Mumtaz, Mirrah, Batool, Asra, Ukleja, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922264/
https://www.ncbi.nlm.nih.gov/pubmed/35479589
http://dx.doi.org/10.20524/aog.2022.0696
Descripción
Sumario:BACKGROUND: The aim of this study was to determine clinical predictors of gastroparesis outcomes. METHODS: Between September 30, 2009 and January 31, 2020, we identified patients with gastroparesis diagnosed based on a (99m)Tc sulfur-labeled gastric emptying test. The patients who had no symptom improvement at 4 and 12 weeks were considered to have failed to show clinical improvement. Logistic regression was used to compute the association between different factors and clinical outcomes. RESULTS: We identified 320 patients (mean age 47.5±5.3 years, 70.3% female, 71.3% Whites). Failure of clinical improvement was seen in 34.7% patients at 4 weeks and 27.5% at 12 weeks after the gastroparesis diagnosis. At 4 weeks, chronic kidney disease (adjusted odds ratio [aOR] 2.62, 95% confidence interval [CI] 1.31-5.26; P=0.007) and body mass index (BMI) <18.5 kg/m(2) (aOR 9.90, 95%CI 2.98-32.93; P<0.001) were associated with a lack of improvement, whereas type 2 diabetes mellitus (T2DM) was associated with better clinical outcomes (aOR 0.50, 95%CI 0.25-0.99; P=0.047). At 12 weeks, subjects who had undergone post-bariatric surgery had no improvement of their gastroparesis symptoms (aOR 2.43, 95%CI 1.01-5.82; P=0.047), whereas T2DM was associated with clinical improvement (aOR 0.46, 95%CI 0.22-0.95; P=0.035). The subgroup analysis showed that BMI <18.5 kg/m(2) in non-diabetics and peripheral neuropathy in diabetics were associated with persistent symptoms. CONCLUSIONS: Gastroparesis patients with T2DM had significant symptom improvement. A history of bariatric surgery and renal failure were associated with worse clinical improvement. Peripheral neuropathy in diabetics was associated with persistent symptoms.